Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRMDNASDAQ:LIVNNASDAQ:LMATNASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRMDIradimed$53.47+1.0%$52.33$41.60▼$63.29$679.87M0.9143,591 shs27,389 shsLIVNLivaNova$36.780.0%$37.98$32.48▼$64.48$2.01B0.84608,417 shs925,924 shsLMATLeMaitre Vascular$78.70-12.8%$85.58$71.42▼$109.58$1.78B0.89162,250 shs601,984 shsNVCRNovoCure$18.15+1.1%$18.14$14.17▼$34.13$2.02B0.731.17 million shs728,550 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRMDIradimed0.00%+0.28%+7.11%-9.91%+19.62%LIVNLivaNova0.00%-1.29%+2.31%-23.47%-42.67%LMATLeMaitre Vascular0.00%-14.09%-1.35%-17.53%+6.04%NVCRNovoCure0.00%-1.89%+10.07%-23.58%+22.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRMDIradimed4.8372 of 5 stars3.52.02.54.43.33.31.9LIVNLivaNova3.7963 of 5 stars4.43.00.00.03.61.71.3LMATLeMaitre Vascular2.775 of 5 stars2.31.03.30.02.53.31.3NVCRNovoCure3.9912 of 5 stars3.33.00.04.53.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRMDIradimed 3.00Buy$72.0034.65% UpsideLIVNLivaNova 2.88Moderate Buy$61.1766.30% UpsideLMATLeMaitre Vascular 2.63Moderate Buy$98.1424.71% UpsideNVCRNovoCure 2.67Moderate Buy$32.8380.90% UpsideCurrent Analyst Ratings BreakdownLatest IRMD, LMAT, NVCR, and LIVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.003/17/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.003/7/2025LIVNLivaNovaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $56.003/3/2025LIVNLivaNovaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $55.002/28/2025LMATLeMaitre VascularLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$105.00 ➝ $110.002/28/2025LMATLeMaitre VascularOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/28/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/26/2025LIVNLivaNovaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $60.002/26/2025LIVNLivaNovaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $60.00(Data available from 5/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRMDIradimed$73.24M9.28$1.33 per share40.12$5.66 per share9.45LIVNLivaNova$1.25B1.60$3.30 per share11.15$23.72 per share1.55LMATLeMaitre Vascular$219.86M8.09$1.39 per share56.52$13.38 per share5.88NVCRNovoCure$621.71M3.25N/AN/A$3.39 per share5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRMDIradimed$19.23M$1.5035.6526.74N/A26.26%24.12%21.20%5/5/2025 (Estimated)LIVNLivaNova$17.55M$1.1487.5711.71N/A1.91%13.81%7.07%5/7/2025 (Estimated)LMATLeMaitre Vascular$30.10M$1.9443.0136.272.2219.40%13.15%11.47%N/ANVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)Latest IRMD, LMAT, NVCR, and LIVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025LIVNLivaNova$0.75N/AN/AN/A$302.34 millionN/A5/5/2025Q1 2025IRMDIradimed$0.43N/AN/AN/A$19.33 millionN/A5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million2/27/2025Q4 2024LMATLeMaitre Vascular$0.49$0.49N/A$0.49$55.99 million$55.81 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million2/13/2025Q4 2024IRMDIradimed$0.45$0.40-$0.05$0.40$19.09 million$19.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRMDIradimed$0.681.27%N/A45.33%N/ALIVNLivaNovaN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.801.02%+13.30%41.24%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest IRMD, LMAT, NVCR, and LIVN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/20252/18/2025LMATLeMaitre Vascularquarterly$0.200.9%3/13/20253/13/20253/27/20252/6/2025IRMDIradimedquarterly$0.171.1%2/24/20252/24/20253/5/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRMDIradimedN/A9.217.82LIVNLivaNova0.463.372.87LMATLeMaitre VascularN/A7.745.52NVCRNovoCure0.271.491.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRMDIradimed92.34%LIVNLivaNova97.64%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipIRMDIradimed37.10%LIVNLivaNova0.27%LMATLeMaitre Vascular10.79%NVCRNovoCure6.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRMDIradimed11012.72 million7.97 millionOptionableLIVNLivaNova2,90054.52 million54.15 millionOptionableLMATLeMaitre Vascular49022.59 million20.06 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableIRMD, LMAT, NVCR, and LIVN HeadlinesRecent News About These CompaniesPDT Partners LLC Trims Holdings in NovoCure Limited (NASDAQ:NVCR)May 2 at 6:32 AM | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Price T Rowe Associates Inc. MDMay 2 at 4:36 AM | marketbeat.comEmerald Mutual Fund Advisers Trust Makes New Investment in NovoCure Limited (NASDAQ:NVCR)May 1, 2025 | marketbeat.com200,000 Shares in NovoCure Limited (NASDAQ:NVCR) Acquired by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comWall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?April 29, 2025 | zacks.comT. Rowe Price Investment Management Inc. Trims Holdings in NovoCure Limited (NASDAQ:NVCR)April 28, 2025 | marketbeat.comInvesco Ltd. Acquires 79,698 Shares of NovoCure Limited (NASDAQ:NVCR)April 28, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Cut to "Sell" at StockNews.comApril 27, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call TranscriptApril 25, 2025 | msn.comWhy NovoCure Stock Skyrocketed This WeekApril 25, 2025 | fool.comNovocure outlines expansion plans for lung cancer treatment and regulatory milestones in 2025April 25, 2025 | msn.comMarshall Wace LLP Has $8.07 Million Holdings in NovoCure Limited (NASDAQ:NVCR)April 25, 2025 | marketbeat.comPiper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock PriceApril 25, 2025 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Shares Gap Up After Earnings BeatApril 25, 2025 | americanbankingnews.comNovocure’s NSCLC launch momentum ‘positive,’ says H.C. WainwrightApril 24, 2025 | markets.businessinsider.comWhy NovoCure Stock Leaped 4% Higher TodayApril 24, 2025 | fool.comNovocure reports Q1 EPS (31c), consensus (46c)April 24, 2025 | markets.businessinsider.comWhy NovoCure Limited’s (NVCR) Stock Is Up 7.54%April 24, 2025 | aaii.comNovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025April 24, 2025 | benzinga.comNovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesApril 24, 2025 | zacks.comNovoCure Surpasses Q1 ExpectationsApril 24, 2025 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRMD, LMAT, NVCR, and LIVN Company DescriptionsIradimed NASDAQ:IRMD$53.47 +0.53 (+1.00%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$53.46 -0.02 (-0.03%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.LivaNova NASDAQ:LIVN$36.78 -0.01 (-0.03%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$36.78 -0.01 (-0.01%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.LeMaitre Vascular NASDAQ:LMAT$78.70 -11.54 (-12.79%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$82.12 +3.43 (+4.35%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$18.15 +0.20 (+1.11%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$18.45 +0.30 (+1.65%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Why Energy Stocks Like Exxon and Hess Are Back in Focus Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Western Digital: Is the Storage Sector Set for a Rebound? Wingstop Stock Jumps on Q1 Beat, Expansion Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
